Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine in Late Onset Parkinson's Disease
NCT02103465Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Cardinale G. Panico
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Rotigotine with Placebo (2 arms). Primary endpoint: Percentage of Responders to treatment in motor (part III) and Activities of daily living (ADL) (part II) components of Unified Parkinson's Disease Rating Scale. Started Dec 2013; status: terminated.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02103465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103465.